SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Daisuke Morihara, Hiroshi Watanabe, Kazuhide Takata, Hideyuki Iwashita, Naoaki Tsuchiya, Hideo Kunimoto, Shizuka Kuno, Atsushi Fukunaga, Kaoru Yotsumoto, Takashi Tanaka, Kunitoshi Sakurai, Genryu Hirano, Keiji Yokoyama, Shinya Nishizawa, Makoto Yoshikane, Akira Anan, Yasuaki Takeyama, Yuji Kitamura, Kaoru Iwata, Makoto Irie, Satoshi Shakado, Tetsuro Sohda, Shotaro Sakisaka, Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate, European Journal of Gastroenterology & Hepatology, 2015, 27, 1, 55

    CrossRef

  2. 2
    Véronique Loustaud-Ratti, Annick Rousseau, Paul Carrier, Chanlina Vong, Tristan Chambaraud, Jérémie Jacques, Marilyne Debette-Gratien, Denis Sautereau, Marie Essig, eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?, Liver International, 2015, 35, 1
  3. 3
    Dario Sacchini, Lucia Craxì, Pietro Refolo, Roberta Minacori, Americo Cicchetti, Antonio Gasbarrini, Calogero Cammà, Antonio G. Spagnolo, Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors, Digestive and Liver Disease, 2015, 47, 5, 351

    CrossRef

  4. 4
    Elizabeth C. Verna, Jacqueline G. O’Leary, Hepatitis C treatment in patients on the liver transplant waiting list, Current Opinion in Organ Transplantation, 2015, 20, 3, 242

    CrossRef

  5. 5
    Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie, Etienne Brochot, Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations, The Journal of Clinical Pharmacology, 2015, 55, 5
  6. 6
    Antonio Rivero-Juarez, Angela Camacho, Antonio Rivero, Pharmacokinetic and pharmacodynamic evaluation of telaprevir for the treatment of hepatitis C, Expert Opinion on Drug Metabolism & Toxicology, 2015, 11, 7, 1157

    CrossRef

  7. 7
    Fenglei Huang, Viktoria Moschetti, Benjamin Lang, Atef Halabi, Marc Petersen-Sylla, Chan-Loi Yong, Mabrouk Elgadi, Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment, Antimicrobial Agents and Chemotherapy, 2015, 59, 1, 251

    CrossRef

  8. 8
    Eva Van den Eynde, Jordi Curto, Elena Ferrer, Arkaitz Imaz, Maria Saumoy, Silvana Di Yacovo, Antonia Vila, Daniel Podzamczer, Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients, AIDS, 2015, 29, 8, 977

    CrossRef

  9. 9
    Laura Andreocchi, Valeriu Toma, Aliza Canonica-Lepori, Lorenzo Magenta, Sandor Györik, Lisa Pellegrini, Enos Bernasconi, Telaprevir-induced renal impairment: three clinical cases and a review of the literature, Infectious Diseases, 2015, 47, 9, 662

    CrossRef

  10. 10
    T. Oze, N. Hiramatsu, T. Yakushijin, R. Yamada, N. Harada, N. Morishita, M. Oshita, E. Mita, T. Ito, Y. Inui, M. Inada, S. Tamura, H. Yoshihara, Y. Imai, M. Kato, T. Miyagi, Y. Yoshida, T. Tatsumi, A. Kasahara, N. Hayashi, T. Takehara, The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1, Journal of Viral Hepatitis, 2015, 22, 3
  11. 11
    Amedeo De Nicolò, Adnan Mohamed Abdi, Lucio Boglione, Lorena Baiett, Sarah Allegra, Giovanni Di Perri, Antonio D’Avolio, UPLC–MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells, Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 443

    CrossRef

  12. 12
    James R. Burton, Jacqueline G. O’Leary, Elizabeth C. Verna, Varun Saxena, Jennifer L. Dodge, Richard T. Stravitz, Joshua Levitsky, James F. Trotter, Gregory T. Everson, Robert S. Brown, Norah A. Terrault, A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy, Journal of Hepatology, 2014, 61, 3, 508

    CrossRef

  13. 13
    Eva Van den Eynde, Elena Ferrer, Daniel Podzamczer, Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir, AIDS, 2014, 28, 10, 1538

    CrossRef

  14. 14
    V. Virlogeux, P. Pradat, F. Bailly, G. Funingana, F. Gonçalves, M. Maynard, K. Hartig-Lavie, M. Amiri, F. Zoulim, Boceprevir and telaprevir-based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score, Journal of Viral Hepatitis, 2014, 21, 9
  15. 15
    Patrizia Burra, Kryssia I. Rodríguez-Castro, Francesco Marchini, Luciana Bonfante, Lucrezia Furian, Alberto Ferrarese, Alberto Zanetto, Giacomo Germani, Francesco Paolo Russo, Marco Senzolo, Hepatitis C virus infection in end-stage renal disease and kidney transplantation, Transplant International, 2014, 27, 9
  16. 16
    Massimo Tempestilli, Raffaella Lionetti, Gianpiero D'Offizi, Marzia Montalbano, Andrea Giaffreda, Simone Fazio, Leopoldo P. Pucillo, Increased plasma concentration of ribavirin as a result of renal dysfunction in hepatitis C virus patients treated with telaprevir, Hepatology, 2014, 60, 3
  17. 17
    Kevin Humphries, Jama M. Darling, A. Sidney Barritt, Membranoproliferative Glomerulonephritis, Type II Cryoglobulinemia and Triple Therapy for Hepatitis C: A Case Series and Review of the Literature, Digestive Diseases and Sciences, 2014, 59, 8, 2007

    CrossRef

  18. 18
    Sarah Zimner-Rapuch, Nicolas Janus, Gilbert Deray, Vincent Launay-Vacher, New Therapies for Hepatitis C: Considerations in Patients with Renal Impairment, Drugs, 2014, 74, 12, 1307

    CrossRef

  19. 19
    André-Jean Rémy, Bruno Lesgourgues, Bernard Nalet, Xavier Causse, Jean Henrion, Jacques Denis, Ramuntxo Arotçarena, Hervé Hagège, Alexandre Pariente, Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C, European Journal of Gastroenterology & Hepatology, 2014, 26, 9, 996

    CrossRef

  20. 20
    Umberto Vespasiani-Gentilucci, Paolo Gallo, Antonio Picardi, Renal impairment and anemia during triple therapy, Journal of Hepatology, 2014, 60, 5, 1099

    CrossRef

  21. 21
    Véronique Loustaud-Ratti, Paul Carrier, Chanlina Vong, Marie Essig, Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir, Hepatology, 2014, 59, 6
  22. 22
    Zulane Veiga, Gustavo H.S. Pereira, Flávia F. Fernandes, Daniela M. Mariz, João L. Pereira, Reply to, European Journal of Gastroenterology & Hepatology, 2014, 26, 6, 687

    CrossRef

  23. 23
    Manuel Romero-Gómez, Marina Berenguer, Esther Molina, Jose-Luis Calleja, Reply to: “Renal impairment and anemia during triple therapy”, Journal of Hepatology, 2014, 60, 5, 1100

    CrossRef

  24. 24
    Harald Farnik, Nerea Ferreirós, Sandra Labocha, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren, Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection, Scandinavian Journal of Gastroenterology, 2014, 49, 12, 1473

    CrossRef

  25. 25
    Tetsuo Takehara, Simeprevir for the treatment of chronic hepatitis C genotype 1 infection, Expert Review of Anti-infective Therapy, 2014, 12, 8, 909

    CrossRef

  26. 26
    A. Kyvernitakis, E. Jabbour, H. A. Torres, Sustained Virologic Response After 6 Weeks of Therapy With a First-Generation Hepatitis C Virus Protease Inhibitor, Clinical Infectious Diseases, 2014, 58, 9, 1342

    CrossRef

  27. 27
    Amedeo De Nicolò, Lucio Boglione, Alessia Ciancio, Jessica Cusato, Silvia Strona, Chiara Simona Cardellino, Adnan Mohamed Abdi, Giuseppe Cariti, Giulia Troshina, Gian Paolo Caviglia, Antonina Smedile, Mario Rizzetto, Giovanni Di Perri, Antonio D’Avolio, Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner, Antiviral Research, 2014, 109, 7

    CrossRef